{"id":85227,"date":"2023-05-03T10:01:59","date_gmt":"2023-05-03T15:01:59","guid":{"rendered":"http:\/\/www.kateva.org\/sh\/?p=85227"},"modified":"2023-05-03T10:01:59","modified_gmt":"2023-05-03T15:01:59","slug":"lillys-donanemab-for-alzheimer-early-trial-results-47-of-patients-had-no-clinical-progression-on-the-cdr-sb-after-one-year-which-sounds-quite-interesting-but-has-to-be-compa","status":"publish","type":"post","link":"http:\/\/www.kateva.org\/sh\/?p=85227","title":{"rendered":"Lilly&#8217;s Donanemab for Alzheimer &#8211; early trial results: &#8220;47% of patients \u201chad no clinical progression\u201d on the CDR-SB after one year, which sounds quite interesting, but has to be compared to 29% of the patients in the placebo group who had no progressi"},"content":{"rendered":"<p><a href=\"https:\/\/www.science.org\/content\/blog-post\/lilly-s-new-donanemab-data-alzheimer-s\">Link<\/a>. This is at best a mediocre drug for people with Alzheimer&#8217;s and probably it&#8217;s useless. But maybe there&#8217;s a subtype of the dementia where it&#8217;s a good drug (albeit with very dangerous side effects).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Link. This is at best a mediocre drug for people with Alzheimer&#8217;s and probably it&#8217;s useless. But maybe there&#8217;s a subtype of the dementia where it&#8217;s a good drug (albeit with very dangerous side effects).<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[32],"class_list":["post-85227","post","type-post","status-publish","format-standard","hentry","category-share","tag-pinboard"],"_links":{"self":[{"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=\/wp\/v2\/posts\/85227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=85227"}],"version-history":[{"count":1,"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=\/wp\/v2\/posts\/85227\/revisions"}],"predecessor-version":[{"id":85228,"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=\/wp\/v2\/posts\/85227\/revisions\/85228"}],"wp:attachment":[{"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=85227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=85227"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.kateva.org\/sh\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=85227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}